Skip to content

Safety Study of Endobronchial Transplantation of Autologous Mesenchymal Stem Cells (MSCs) in Emphysema Patients

Safety Study of Endobronchial Transplantation of Autologous Mesenchymal Stem Cells Derived Bone Marrow in Patients With Emphysema

Status
UNKNOWN
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01758055
Enrollment
12
Registered
2012-12-31
Start date
2012-12-31
Completion date
2014-01-31
Last updated
2012-12-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Emphysema

Keywords

Mesenchymal stem cell, emphysema, lung function

Brief summary

The purpose of this study is evaluating the safety of endobronchial transplantation of autologous mesenchymal stem cells derived bone marrow in patients with emphysema.

Detailed description

Chronic obstructive pulmonary disease (COPD) is a worldwide epidemic disease that the global prevalence of it was estimated to be approximately 210 million individuals and accounting for more than three million deaths annually. And currently, it is the fifth chief cause of death in the United State of America. COPD is characterized by chronic, irreversible inflammation of the airways and has two pathologic features, emphysema and bronchiolitis. The most relevant feature in the lung emphysema is airflow limitation, resulting from the loss of alveolar wall and enlargement of alveolar space distal to the terminal bronchiole. Cigarette and air pollution are the most major factors for developing COPD. Unfortunately, aside from supplemental domiciliary oxygen for the small number of patients who demonstrate resting arterial hypoxemia and smoking cessation for continued smokers, there are no interventions that have been unequivocally shown to prolong survival in patients with COPD. In the preprocessing phase, patients will underwent a complete evaluation of the pulmonary function test with spirometer to measure the FEV1, FVC, FEV1/FVC, cardiac evaluation (clinical examination, six minute walk test, echocardiography TTE(transthoracic echocardiography ), and electrocardiography),chest X-ray, chest computed tomography scan (helical/high resolution),o2 saturation by oximeter, as well as routine laboratory tests (blood gas, urinalysis, coagulation, complete blood count (CBC), blood urea nitrogen, fasting glucose, creatinine, AST(aspartate aminotransferase), ALT(alanine aminotransferase), C-reactive protein, serology for hepatitis B and C, antihuman immunodeficiency virus, and treponemal test for syphilis (FTA-ABS)). The Dyspnea Scale Score test, modified according to the British MMRC, was also conducted, according to Mahler and Wells and Curley.And quality of life measures will assess according to SF-36(Medical Outcomes Study 36-Items Short-Form Health Survey) questioner. Patients will taken to the operating room, placed in a prone position, and administer a spinal anesthesia. Approximately, 120 mL of bone marrow will aspirated from each puncture and after preparation about 60 million autologous MSCs will transplant by bronchoscopy into the endobronchial of these patients.

Interventions

BIOLOGICALAutologous MSCs transplantation

Autologous mesenchymal stem cells derived bone marrow, bronchoscopy

Sponsors

Royan Institute
CollaboratorOTHER_GOV
Arda Kiani
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
16 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* • Inclusion criteria were as follows: * patients with moderate to severe emphysema that has a FEV1≤50% (approved by HRCT) * aged less than 70 years * no tobacco use for at least 12 months before the protocol application * no serious coronaropathy and/or ventricular dysfunction * no significant renal illness and/or hepatitis * EF(ejection fraction)\>50% * Creatinine \< 2 * AST, ALT≤ 10 times of its normal basis

Exclusion criteria

*

Design outcomes

Primary

MeasureTime frameDescription
forced vital capacity( FVC), forced expiratory volume(FEV1), FEV1/FVCBaseline and one year after procedure* A pulmonary function test that measures the volume and speed of inhaled air. * A pulmonary function test that measures the volume and speed of exhaled air.

Secondary

MeasureTime frameDescription
six minute walk testBaseline and One year after procedure•A six minute walk test with treadmills

Other

MeasureTime frameDescription
DLCO(diffusion capacity of lung for carbon monoxide)Baseline and One year after procedure•Body Box device for evaluating diffusing capacity of the lung for carbon monoxide
CT scanBaseline and One year after procedure•A CT scan for evaluating the changes
Quality of lifeBaseline and One year after procedure•A SF36 quality of life questioner for evaluating the quality of life
Atrial blood gases test-PaO2(partial pressure of oxygen in blood) , PaCO2(partial pressure of carbon dioxide in blood)Baseline and one year after procedure* presence of oxygen in blood gases * presence of carbon dioxide in blood gases
InfectionBaseline and one year after procedure•A CBC test for evaluating the infection
dyspnea scoreBaseline and One year after procedure•A MMRC(modified medical research council) scale for evaluating the dyspnea score
oxygen saturationBaseline and one year after procedure•An oximeter test for evaluating the oxygen saturation

Countries

Iran

Contacts

Primary ContactArda Kiani, MD,PULMONO
Kiani@nritld.ac.ir0098-021-27122171
Backup ContactNaser Aghdami, MD, PHD
nasser.aghdami@royaninstitute.org0098-021-22172330

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026